ArticlePsychopharmacology2011
Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder.
Article in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Convergent functional effects of antidepressants in major depressive disorder: a neuroimaging meta-analysis.Molecular psychiatry · 2025Pooled it
- Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.The international journal of neuropsychopharmacology · 2014Trial
- Age effects on serotonin receptor 1B as assessed by PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2012Trial
- Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data.Molecular psychiatry · 2026Article
- Distance-related functional connectivity alterations in first-episode, drug-naïve major depressive disorder: a resting-state fMRI study with atlas-based neurotransmitter correlates.BMC psychiatry · 2026Article
- The serotonin transporter and the serotonin 1B receptor in relation to social cognition in healthy adults.EJNMMI research · 2026Article
- Neural correlates of distance-related functional reorganization in obsessive compulsive disorder.Journal of psychiatry & neuroscience : JPN · 2026Article
- Mapping neurophysiological and molecular profiles of heterogeneity and homogeneity in schizophrenia-bipolar disorder.Science advances · 2025Article
- Two subtypes of major depressive disorder are identified from individualized gray matter morphological abnormalities in a large multi-site dataset.Psychological medicine · 2025Article
- Network spreading and local biological vulnerability in amyotrophic lateral sclerosis.Communications biology · 2025Article
- Mapping the microstructure of human cerebral cortex in vivo with diffusion MRI.Communications biology · 2025Article
- Benchmarking methods for mapping functional connectivity in the brain.Nature methods · 2025Article
- Mapping cerebral blood perfusion and its links to multi-scale brain organization across the human lifespan.PLoS biology · 2025Article
- Disrupted intersubject variability architecture in structural and functional brain connectomes in major depressive disorder.Psychological medicine · 2025Article
- Common neuroanatomical differential factors underlying heterogeneous gray matter volume variations in five common psychiatric disorders.Communications biology · 2025Article
- Individualized gray matter morphological abnormalities unveil two neuroanatomical obsessive-compulsive disorder subtypes.Translational psychiatry · 2025Article
- Cafeteria Diet Abstinence Induces Depressive Behavior and Disrupts Endocannabinoid Signaling in Dopaminergic Areas: A Preclinical Study.Current neuropharmacology · 2025Article
- Using individualized structural covariance networks to analyze the heterogeneity of cerebral small vessel disease with depressive states.Frontiers in neurology · 2025Article
- Integrating brainstem and cortical functional architectures.Nature neuroscience · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleAlthough serotonin (5-HT) dysregulation is implicated in the pathophysiology of major depressive disorder (MDD), the role of specific receptor subtypes remains to be elucidated. Emerging preclinical research suggests an important role for the 5-HT(1B) receptor in behavioral regulation and depressive phenotypes. In particular, 5-HT(1B) heteroreceptors located within the striatum have been shown to play an essential role in antidepressant action.
objectivesThe objective of this study was to determine 5-HT(1B) receptor binding potential (BP (ND)) in the region of the ventral striatum/ventral pallidum (VS/VP) in individuals with MDD and healthy control participants.
methodsTen participants with MDD (30.8 ± 9.5 years, five men/five women) in a current major depressive episode (MDE) and ten healthy control participants (30.7 ± 10.5 years, five men/five women) underwent positron emission tomography (PET) scanning with the selective 5-HT(1B) receptor radioligand [(11)C]P943.
resultsWithin the VS/VP region of interest, [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 ± 0.13 and 1.68 ± 0.16, respectively; 18.7% between-group difference; p < 0.001).
conclusionsConsistent with preclinical and postmortem data, our findings suggest abnormally reduced function of VS/VP 5-HT(1B) receptors in humans with MDD. Abnormal 5-HT(1B) heteroreceptor function may contribute to dysfunctional reward signaling within the striatum, including the nucleus accumbens, via interaction with dopamine, γ-amino-butyric acid, or glutamate systems. Our findings suggest reduced 5-HT(1B) receptor signaling in the VS/VP in MDD and contribute to the therapeutic rationale for testing 5-HT(1B) agonists as a novel class of antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.